BR9910035A - Derivados de guanidina - Google Patents

Derivados de guanidina

Info

Publication number
BR9910035A
BR9910035A BR9910035-5A BR9910035A BR9910035A BR 9910035 A BR9910035 A BR 9910035A BR 9910035 A BR9910035 A BR 9910035A BR 9910035 A BR9910035 A BR 9910035A
Authority
BR
Brazil
Prior art keywords
derivatives
guanidine
guanidine derivatives
diseases
arteriosclerosis
Prior art date
Application number
BR9910035-5A
Other languages
English (en)
Inventor
Kohei Takenaka
Yoshikazu Inoue
Masatoshi Minagawa
Atsushi Akahane
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP3171A external-priority patent/AUPP317198A0/en
Priority claimed from AUPP8311A external-priority patent/AUPP831199A0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR9910035A publication Critical patent/BR9910035A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/10—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

"DERIVADOS DE GUANIDINA", tendo a seguinte fórmula: na qual cada símbolo é como definido na descrição. A invenção refere-se ainda a um sal de guanidina farmaceuticamente aceitável, aos processos para preparar os referidos derivados, à composição farmacêutica compreendendo os referidos derivados, e a um uso dos referidos derivados para tratar doenças cardiovasculares, doenças cerebrovasculares, doenças renais, arteriosclerose, choque e similares, em seres humanos e animais.
BR9910035-5A 1998-04-24 1999-04-19 Derivados de guanidina BR9910035A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP3171A AUPP317198A0 (en) 1998-04-24 1998-04-24 New compound
AUPP8311A AUPP831199A0 (en) 1999-01-25 1999-01-25 New compound
PCT/JP1999/002088 WO1999055690A1 (en) 1998-04-24 1999-04-19 Guanidine derivatives

Publications (1)

Publication Number Publication Date
BR9910035A true BR9910035A (pt) 2000-12-26

Family

ID=25645769

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910035-5A BR9910035A (pt) 1998-04-24 1999-04-19 Derivados de guanidina

Country Status (8)

Country Link
US (1) US6346527B1 (pt)
EP (1) EP1073650A1 (pt)
JP (1) JP2002513013A (pt)
KR (1) KR20010042618A (pt)
CN (1) CN1307571A (pt)
BR (1) BR9910035A (pt)
CA (1) CA2325736A1 (pt)
WO (1) WO1999055690A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW462964B (en) * 1998-05-26 2001-11-11 Sumitomo Pharma Guanidine derivatives for the treatment and prevention of disorders caused by inhibiting hyperactivity of Na/H exchange transport system and process for producing the same
CA2345459A1 (en) * 1998-11-12 2000-05-18 Regine Bohacek Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
AU4360200A (en) * 1999-04-23 2000-11-10 Bristol-Myers Squibb Company Bicyclic acyl guanidine sodium/proton exchange inhibitors and method
US6627651B1 (en) * 1999-05-07 2003-09-30 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
US6734205B2 (en) 1999-12-16 2004-05-11 Sumitomo Pharmaceuticals Company Limited Substituted guanidine derivatives
KR20030005202A (ko) * 2000-02-21 2003-01-17 다케다 야쿠힌 고교 가부시키가이샤 환상 화합물의 제조 방법
GB0121622D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
WO2003040127A1 (en) * 2001-11-02 2003-05-15 G.D. Searle Llc Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
JP2003187146A (ja) * 2001-12-17 2003-07-04 Matsushita Electric Ind Co Ltd データ提供サービスシステム
US20050261164A1 (en) * 2002-07-09 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Remedy for urinary frequency and urinary incontinence
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
RU2591188C2 (ru) 2010-11-08 2016-07-10 Альбирео Аб Ингибиторы ibat для лечения заболеваний печени
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP3802504B1 (en) 2018-06-05 2023-01-18 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11802115B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2023504644A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
IL293379A (en) 2019-12-04 2022-07-01 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
CN116583504A (zh) 2020-12-04 2023-08-11 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4328352A1 (de) * 1993-08-24 1995-03-02 Hoechst Ag Substituierte N,N'-Di-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO1998055475A1 (en) * 1997-06-02 1998-12-10 Fujisawa Pharmaceutical Co., Ltd. Guanidine deriviatives as inhibitors of na+/h+ exchange in cells

Also Published As

Publication number Publication date
CN1307571A (zh) 2001-08-08
EP1073650A1 (en) 2001-02-07
JP2002513013A (ja) 2002-05-08
WO1999055690A1 (en) 1999-11-04
US6346527B1 (en) 2002-02-12
CA2325736A1 (en) 1999-11-04
KR20010042618A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
BR9910035A (pt) Derivados de guanidina
BR0015908A (pt) Emprego de compostos org nicos no tratamento de doenças
BR9916307A (pt) Derivados quinolina
BR0010530A (pt) Genes de resistência adquirida em plantas
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BR9408407A (pt) Uso de inibidores pla2 como tratamento para doença de alzheimer
BRPI0411900A (pt) compostos antivirais e métodos
BR0213358A (pt) Uso de flibanserina
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
BR0309855A (pt) Pirazolpiridinas substituìdas com carbamato
BR0008840B1 (pt) derivados de camptotecina, processos para a sua preparaÇço, composiÇço farmacÊutica que os compreende e uso dos mesmos.
CO4340735A1 (es) Acido micofenolico 6-sustituido y derivados y procedimiento para su preparacion
BR0113776A (pt) Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição
BR9712808A (pt) Indol-3-glioxilamidas n-substituìdas com efeito antiasmático, anti-alérgico e imunossupressor/imunomodulador
ES2064130T3 (es) Utilizacion de droloxifeno para el tratamiento de enfermedades de los huesos.
BR9810146A (pt) Composto, processo para preparação do mesmo, composição farmacêutica e método para tratar ou prevenir doenças mediadas pela taquicinina
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
BR9917047A (pt) Composto de piperazina, método para prepará-lo, composição farmacêutica contendo-o e seu uso
BR0110968A (pt) Antagonistas dos receptores de il-8
BR9504450A (pt) Agentes herbicidas processo para o combate de ervas daninhas utilizaçao e processo para a preparaçao de agentes herbicidas
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
BR9811298A (pt) Uso de um composto de vanádio fisiologicamente aceitável
BR9503282A (pt) Derivados de piridiltetrazolinona processo para sua preparaçao composiçoes herbicidas processo para combater ervas daninhas uso de derivados de tetrazolinona e processo para preparaçao e composiçoes herbicidas
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]